Clinical Cancer Research Meeting Calendar AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, H.
Right arrow Articles by Aburatani, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, H.
Right arrow Articles by Aburatani, H.
Clinical Cancer Research Vol. 12, 3257-3264, June 1, 2006
© 2006 American Association for Cancer Research


Human Cancer Biology

Identification of ROBO1 as a Novel Hepatocellular Carcinoma Antigen and a Potential Therapeutic and Diagnostic Target

Hirotaka Ito1,5, Shin-ichi Funahashi2,5, Naoko Yamauchi7, Junji Shibahara7, Yutaka Midorikawa1,3, Shigeto Kawai6, Yasuko Kinoshita6, Akira Watanabe1, Yoshitaka Hippo1, Toshihiko Ohtomo5, Hiroko Iwanari4, Atsushi Nakajima8, Masatoshi Makuuchi3, Masashi Fukayama7, Yuichi Hirata5, Takao Hamakubo2, Tatsuhiko Kodama2, Masayuki Tsuchiya5 and Hiroyuki Aburatani1

Authors' Affiliations: 1 Genome Science Division and 2 Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, the University of Tokyo; 3 Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, the University of Tokyo; 4 Perseus Proteomics, Inc., Tokyo, Japan; and 5 Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan; 6 Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan; and 7 Department of Pathology and 8 Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Requests for reprints: Hiroyuki Aburatani, Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan. Phone: 81-3-5452-5352; Fax: 81-3-5452-5355; E-mail: haburata-tky{at}umin.ac.jp.

Purpose: Hepatocellular carcinoma is the most common primary malignancy of the liver and accounts for as many as one million deaths annually worldwide. The present study was done to identify new transmembrane molecules for antibody therapy in hepatocellular carcinoma.

Experimental Design: Gene expression profiles of pooled total RNA from three tissues each of moderately differentiated and poorly differentiated hepatocellular carcinoma were compared with those of normal liver, noncancerous liver tissue in hepatocellular carcinoma patients, 30 normal tissue samples, and five fetal tissue samples. Target genes up-regulated specifically in hepatocellular carcinoma were validated by immunohistochemical analysis and complement-dependent cytotoxicity assay using monoclonal antibodies generated against target molecules.

Results: The human homologue of the Drosophila Roundabout gene, axon guidance receptor homologue 1, ROBO1/DUTT1, a member of the immunoglobulin superfamily, was highly expressed in hepatocellular carcinoma, whereas it showed only a limited distribution in normal tissues. On immunohistochemical analysis using a newly generated anti-ROBO1 monoclonal antibody, positive signals were observed in 83 of 98 cases of hepatocellular carcinoma (84.7%). The mAb B2318C induced complement-dependent cytotoxicity in ROBO1-expressing cell lines and in the liver cancer cell line PLC/PRF/5. Strikingly, the ectodomain of ROBO1 was detected not only in the culture medium of liver cancer cell lines (PLC/PRF/5, HepG2, etc.) but also in sera from hepatocellular carcinoma patients (6 of 11).

Conclusions: This is the first report that ROBO1 is overexpressed in hepatocellular carcinoma and shed into serum in humans. These observations suggest that ROBO1 is a potential new serologic marker for hepatocellular carcinoma and may represent a new therapeutic target.




This article has been cited by other articles:


Home page
J. Virol.Home page
H. Guan, J. F. Williams, and R. P. Ricciardi
Induction of Neuronal and Tumor-Related Genes by Adenovirus Type 12 E1A
J. Virol., January 15, 2009; 83(2): 651 - 661.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Morikawa, A. Sugiyama, H. Kume, S. Ota, T. Kashima, K. Tomita, T. Kitamura, T. Kodama, M. Fukayama, and H. Aburatani
Identification of Toll-Like Receptor 3 as a Potential Therapeutic Target in Clear Cell Renal Cell Carcinoma
Clin. Cancer Res., October 1, 2007; 13(19): 5703 - 5709.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Morlot, N. M. Thielens, R. B. G. Ravelli, W. Hemrika, R. A. Romijn, P. Gros, S. Cusack, and A. A. McCarthy
Structural insights into the Slit-Robo complex
PNAS, September 18, 2007; 104(38): 14923 - 14928.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.